Houlihan Lokey Demonstrates Resilience with Strong Quarterly Performance

Global investment advisory firm Houlihan Lokey has delivered a powerful start to its fiscal year 2026, showcasing precisely why it remains a premier advisor for intricate financial transactions. Against a backdrop of market volatility, the firm has not only posted impressive quarterly results but has also strategically positioned itself within lucrative growth sectors, prompting analysis on whether this momentum can sustainably elevate its share price.

Robust Financial Performance Exceeds Projections

The quarter was marked by significant financial outperformance. Houlihan Lokey reported first-quarter earnings per share (EPS) of $2.14, substantially surpassing analyst consensus estimates of $1.69. Revenue witnessed a notable year-over-year increase of 17.8%, reaching $605.35 million. This growth was broad-based, with all three of the firm’s core service divisions—Corporate Finance, Financial Restructuring, and Financial and Valuation Advisory—contributing positively.

This financial strength has been reflected in the equity’s recent trajectory. Although the stock currently trades approximately 7% below its 52-week peak, it has demonstrated a significant recovery from its lows experienced earlier in the spring.

Strategic Mandates Highlight Market Expertise

The company continues to solidify its standing by securing pivotal advisory roles. It recently acted as the exclusive financial advisor to Hudson Global, Inc. in its all-stock merger with Star Equity Holdings. Following shareholder approval on August 21, this transaction created a new, diversified holding company with pro-forma revenues of approximately $210 million.

Should investors sell immediately? Or is it worth buying Houlihan Lokey?

Concurrently, Houlihan Lokey demonstrated its international capabilities by advising Apelos GmbH, a German healthcare services platform, on a flexible growth financing facility. This capital was instrumental in supporting Apelos’s acquisition of over 50 medical practices, underscoring the firm’s adeptness in managing complex, cross-border capital market operations.

Institutional Investment Activity and Analyst Sentiment

Recent trading activity indicates sustained institutional interest, albeit with a mixed approach. While Raymond James Financial decreased its stake by 4.2%, several other prominent institutions either established new positions or expanded existing ones. Notable entrants and buyers included Bogart Wealth, Mariner LLC, and Barclays PLC. Quantbot Technologies LP, for instance, acquired a new position comprising 20,646 shares. This activity suggests a period of active reassessment of the investment bank’s value by sophisticated market participants.

Shareholders are set to receive a quarterly cash dividend of $0.60 per share, which will be paid on September 15 to shareholders of record as of September 2. This distribution annualizes to a yield of approximately 1.3%.

Analyst opinions present a varied outlook. In June, Morgan Stanley reaffirmed an “Overweight” rating and raised its price target to $192. Keefe, Bruyette & Woods upgraded the stock from “Hold” to “Moderate Buy” in July, setting a target of $232. Conversely, Wall Street Zen downgraded the stock to “Hold” in early August. These divergent ratings highlight the complex valuation landscape within the financial services sector. The central question for Houlihan Lokey is whether its robust quarterly performance is an anomaly or a clear indicator of a durable and effective growth strategy.